MolPharm

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Speno, H. S.
Right arrow Articles by Coyle, J. T.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Speno, H. S.
Right arrow Articles by Coyle, J. T.

Vol. 55, Issue 1, 179-185, January 1999

Site-Directed Mutagenesis of Predicted Active Site Residues in Glutamate Carboxypeptidase II

Henry S. Speno, Ruth Luthi-Carter, Wendy L. Macias, Stacey L. Valentine, Amit R. T. Joshi, and Joseph T. Coyle

Laboratory of Molecular and Developmental Neuroscience, Massachusetts General Hospital-East, Charlestown, Massachusetts

Glutamate carboxypeptidase II (GCP II) catalyzes the extracellular hydrolysis of the neuromodulator N-acetyl-aspartylglutamate to N-acetyl-aspartate and glutamate. GCP II also hydrolyzes gamma -glutamyl bonds in folylpolyglutamate. The predicted amino acid sequence of GCP II displays similarities to aminopeptidases from Streptomyces griseus and Vibrio proteolyticus, whose crystal structures have been determined. These aminopeptidases are cocatalytic zinc metallopeptidases belonging to the peptidase family M28. Specific zinc and substrate ligands have been proposed in GCP II based on the amino acid sequence alignment to these M28 family members. In the present study, site-directed mutagenesis has been used to test the assignment of these putative ligands in human GCP II. Substitutions to the five putative zinc ligands resulted in severely reduced enzyme activity, although mutant protein was expressed as demonstrated by immunoblot analysis. In addition, substitutions of amino acids near the putative zinc ligands have identified other specific residues important for enzyme structure and/or function. Substitutions to putative substrate ligands were less perturbing, and increases in Km were observed for substitutions that introduced a large charge perturbation (e.g., Lys to Glu). The results from substitutions at the proposed zinc and substrate ligands are consistent with the assignment of these residues and suggest that GCP II has a three-dimensional structure similar to other members of the peptidase family M28.

Copyright © 1999 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 J. Biol. Chem.Home page
H. Unno, T. Yamashita, S. Ujita, N. Okumura, H. Otani, A. Okumura, K. Nagai, and M. Kusunoki
Structural Basis for Substrate Recognition and Hydrolysis by Mouse Carnosinase CN2
J. Biol. Chem., October 3, 2008; 283(40): 27289 - 27299.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
M. I. Davis, M. J. Bennett, L. M. Thomas, and P. J. Bjorkman
Crystal structure of prostate-specific membrane antigen, a tumor marker and peptidase
PNAS, April 26, 2005; 102(17): 5981 - 5986.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
A. Ghosh, X. Wang, E. Klein, and W. D.W. Heston
Novel Role of Prostate-Specific Membrane Antigen in Suppressing Prostate Cancer Invasiveness
Cancer Res., February 1, 2005; 65(3): 727 - 731.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Biol. CellHome page
S. A. Rajasekaran, G. Anilkumar, E. Oshima, J. U. Bowie, H. Liu, W. Heston, N. H. Bander, and A. K. Rajasekaran
A Novel Cytoplasmic Tail MXXXL Motif Mediates the Internalization of Prostate-specific Membrane Antigen
Mol. Biol. Cell, December 1, 2003; 14(12): 4835 - 4845.
[Abstract] [Full Text] [PDF]

Home page
 Proc. Natl. Acad. Sci. USAHome page
N. Schulke, O. A. Varlamova, G. P. Donovan, D. Ma, J. P Gardner, D. M. Morrissey, R. R. Arrigale, C. Zhan, A. J. Chodera, K. G. Surowitz, et al.
The homodimer of prostate-specific membrane antigen is a functional target for cancer therapy
PNAS, October 28, 2003; 100(22): 12590 - 12595.
[Abstract] [Full Text] [PDF]

Home page
 Hum Mol GenetHome page
A. M. Devlin, E.-h. Ling, J. M. Peerson, S. Fernando, R. Clarke, A. D. Smith, and C. H. Halsted
Glutamate carboxypeptidase II: a polymorphism associated with lower levels of serum folate and hyperhomocysteinemia
Hum. Mol. Genet., November 1, 2000; 9(19): 2837 - 2844.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 1999 by the American Society for Pharmacology and Experimental Therapeutics